Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation.
Pharmacogenomics
; 20(18): 1291-1302, 2019 12.
Article
em En
| MEDLINE
| ID: mdl-31755847
ABSTRACT
Aims:
To assess stakeholder perspectives regarding the clinical utility of pharmacogenomic (PGx) testing following kidney, liver, and heart transplantation.Methods:
We conducted individual semi-structured interviews and focus groups with kidney, liver, and heart transplantation patients and providers. We analyzed the qualitative data to identify salient themes.Results:
The study enrolled 36 patients and 24 providers. Patients lacked an understanding about PGx, but expressed interest in PGx testing. Providers expressed willingness to use PGx testing, but reported barriers to implementation, such as lack of knowledge, lack of evidence demonstrating clinical utility, and patient healthcare burden.Conclusion:
Patient and provider educational efforts, including foundational knowledge, clinical evidence, and applications to patient care beyond just immunosuppression, may be useful to facilitate the use of PGx testing in transplant medicine.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Farmacogenética
/
Transplante de Órgãos
/
Pessoal de Saúde
/
Medicina de Precisão
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article